Press release,
21 January 2026

Inogen and Biosency combine their expertise to build the first remote monitoring solution with automated data transmission for patients on oxygen therapy

Biosency, a French HealthTech specialized in predictive remote monitoring for patients with chronic respiratory insufficiency, announces a strategic collaboration with Inogen, a global leader in portable oxygen concentrators with over 1.5 million devices delivered worldwide.

This collaboration will enable healthcare professionals to remotely monitor patients on oxygen therapy treatment, all from a unique medical platform designed with and for healthcare professionals. It addresses a long-standing gap in the field of remote monitoring for patients on home oxygen therapy.

Bora care®, Biosency's predictive medicine solution, enables the remote collection of vital signs: heart rate, oxygen saturation, respiratory rate, as well as the patient's activity level. Based on these data, the solution provides an AI-powered alert score to detect COPD exacerbations early. The solution also includes remote monitoring for patients on non-invasive ventilation (NIV).

Through the collaboration with Inogen, Bora connect® will now also provide real-world monitoring data coming from oxygen therapy device combined to patients' vital signs and activity measured by the Bora band® device. This integration brings together Inogen's advanced oxygen technology with Biosency's remote monitoring capabilities, delivering a fully integrated medical platform that enables healthcare professionals to improve the care pathway of patients with chronic respiratory insufficiency.

Improving patient care and supporting proactive clinical management

The shared objective of Inogen and Biosency is to enhance the management of patients on home oxygen therapy by giving healthcare professionals access to monitoring data previously unavailable, and by:

- Strengthening treatment adherence and patient support at home
- Reducing avoidable hospitalizations by enabling earlier detection of changes in the patient's condition
- Improving patient autonomy and quality of life.

By combining oxygen therapy device connectivity with a medical platform dedicated to the remote monitoring of patients with chronic respiratory insufficiency, this partnership enables a comprehensive monitoring of these patients, supporting better clinical management.

"The integration of Inogen's advanced oxygen therapy technology with Biosency's remote monitoring platform represents an important step forward in the support of patients living with chronic respiratory insufficiency," **said Naga Rameswamy, Chief Technology Officer at Inogen.** *"Through this strategic collaboration, we are enabling secure access to real-time device data and clinically relevant insights that help healthcare professionals better understand therapy usage and patient needs. By connecting Inogen's oxygen therapy ecosystem with Biosency's digital platform, we aim to support proactive care management and improved coordination of care for patients receiving therapy at home and beyond."*

"Our mission has always been to improve the at-home management of patients living with COPD. This is why we are committed to innovating and developing technological solutions that address unmet needs, like patients on oxygen therapy, who until now had no workable remote-monitoring options.

It is a real pleasure and a point of pride for us to collaborate with Inogen, a major global player in the field of oxygen therapy. This partnership is fully aligned with our continued efforts to advance care for patients with chronic respiratory insufficiency and to support healthcare professionals with actionable, real-world data," **said Marie Pirotais, CEO of Biosency.**

About Biosency

Founded in 2017, Biosency's mission is to improve home-based care for patients with chronic respiratory insufficiency, particularly COPD, the fourth leading cause of death worldwide. To address this major public health challenge, Biosency has developed Bora care®, a CE Class IIa certified predictive medicine and remote monitoring solution.

Cardiorespiratory and activity data collected through the Bora band® device are complemented by data from non-invasive ventilation (NIV) machines. Centralized on the Bora connect® platform, these data enable continuous monitoring and early detection of exacerbations through the proprietary BVS3 predictive score.

All health data are hosted in France, in compliance with the security and interoperability requirements set by the French Digital Health Agency (ANS). Biosency relies on an international scientific advisory board composed of seven pulmonologists, members of GOLD and the European Respiratory Society (ERS), ensuring the clinical relevance and real-world applicability of its solution.

Learn more: https://biosency.com/en

Press contacts

Biosency

Marie Pirotais – marie.pirotais@biosency.com

Claire Lamour – claire.lamour@biosency.com